Clinical review report: Dexamethasone (Ozurdex) (Allergan, Inc.) indication for the treatment of adult patients with diabetic macular edema who are pseudophakic
Dexamethasone (Ozurdex) has a Health Canada-approved indication for the treatment of macular edema following central retinal vein occlusion, the treatment of noninfectious uveitis affecting the posterior segment of the eye, and for the treatment of adult patients with diabetic macular edema (DME) wh...
| Corporate Author: | |
|---|---|
| Format: | eBook |
| Language: | English |
| Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2018, 2018 Nov
|
| Series: | CADTH common drug review
|
| Subjects: | |
| Online Access: | |
| Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
| Summary: | Dexamethasone (Ozurdex) has a Health Canada-approved indication for the treatment of macular edema following central retinal vein occlusion, the treatment of noninfectious uveitis affecting the posterior segment of the eye, and for the treatment of adult patients with diabetic macular edema (DME) who are pseudophakic. The objective of this review is to perform a systematic review of the beneficial and harmful effects of dexamethasone 700 mcg intravitreal injection for the treatment of adults with DME who are pseudophakic |
|---|---|
| Physical Description: | 1 online resource |